Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 14, 2014 - Issue 2
Submit an article Journal homepage
63
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer?

Ioannis D XynosDepartment of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK
,
Nikhil TannaDepartment of Medical Oncology, Imperial College Healthcare NHS Trust, London, UK
,
Darren K PattenDepartment of Surgery, Imperial College Healthcare NHS Trust, UK, London
&
Carlo PalmieriCorrespondence[email protected]
Pages 163-172 | Published online: 04 Dec 2013

References

  • Forouzanfar MH, Foreman KJ, Delossantos AM et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378, 1461–1484 (2011).
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57–70 (2000).
  • Schneider BP, Sledge GW Jr. Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? J. Clin. Oncol. 29, 2444–2447 (2011).
  • Gianni L, Romieu G, Lichinitser M et al. AVEREL: a randomized phase III trial evaluate bevacizumab (BEV) in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J. Clin. Oncol. 31, 1719–1725 (2013).
  • Gimbrone MA Jr, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136, 261–276 (1972).
  • Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
  • Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133, 275–288 (1971).
  • Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1983).
  • Connolly DT, Olander JV, Heuvelman D et al. Human vascular permeability factor. Isolation from U937 cells. JBC 264, 20017–20024 (1989).
  • Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851–858 (1989).
  • Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a sedreted angiogenic mitogen. Science 246, 1306–1309 (1989).
  • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med. 9, 669–676 (2003).
  • Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963–969 (1997).
  • Nakopoulou L, Stefanaki K, Panayotopoulou E et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum. Pathol. 33, 863–870 (2002).
  • Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1–8 (1991).
  • Gasparini G, Weidner N, Bevilacqua P et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol. 12, 454–466 (1994).
  • Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res. Treat 36, 193–204 (1995).
  • Eppenberger U, Kueng W, Schlaeppi JM et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J. Clin. Oncol. 16, 3129–3136 (1998).
  • Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. JNCI 89, 139–147 (1997).
  • Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int. J. Ca. 89, 51–62 (2000).
  • Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 61, 5407–5414 (2001).
  • Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).
  • Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J. Clin. Oncol. 27, 4966–4972 (2009).
  • Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239–3247 (2010).
  • Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252–1260 (2011).
  • Brufsky AM, Hurvitz S, Perez E et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 29, 4286–4293 (2011).
  • Miles DW, Romieu G, Dieras V et al. Meta-analysis of patients (pts) previously treated with taxanes from three randomized trials of bevacizumab (bv) and first line chemotherapy as treatment for metastatic breast cancer (mbc). Ann. Oncol.21(Suppl. 8), viii9 (2010).
  • Rugo HS, Stopeck AT, Joy AA et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J. Clin. Oncol. 29, 2459–2465 (2011).
  • Bergh J, Bondarenko IM, Lichinitser MR et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase iii study. J. Clin. Oncol. 30, 921–929 (2012).
  • Robert NJ, Saleh MN, Paul D et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin. Breast Cancer 11, 82–92 (2011).
  • Baselga J, Segalla JG, Roche H et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J. Clin. Oncol. 30, 1484–1491 (2012).
  • Miles DW, de Haas SL, Dirix LY et al. Plasma biomarker analyses in the AVADO phase iii randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer. Br. J. Cancer 108, 1052–1060 (2013).
  • Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583–592 (2006).
  • Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Prac. Oncol. 3, 24–40 (2006).
  • Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 67, 7055–7058 (2007).
  • Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964–967 (1997).
  • Shaked Y, Henke E, Roodhart JM et al. (2008). Rapid chemotherapy–induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263–273 (2008)
  • Furstenberger, G, von Moos, R, Lucas R et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy or primary breast cancer. Br. J. Cancer 94, 524–531 (2006)
  • Roodhart JM, Langenberg MH, Vermaat JS et al. Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 12, 87–94 (2010).
  • NHS Commissioning Board Standard Operating Procedures: The Cancer Drugs Fund (CDF). Guidance to support operation of the CDF in 2013-14, NSSCB/SOP03 (March 2013).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.